An integrated genomic and lipidomic approach to human hepatic fat accumulation

描述（由申请方提供）：本研究的最终目标是使用整合基因组学和脂质组学（即脂质家族）数据的系统方法，确定控制人肝脏中各种脂质蓄积的遗传因素。肝脏脂肪蓄积是非酒精性脂肪性肝病（NAFLD）和各种代谢并发症的标志。其机制，特别是脂肪积累的遗传基础，尚未完全阐明。这在很大程度上归因于对脂质代谢和体内平衡的复杂性认识不足。由于广泛的脂质参与脂肪积累和相关的代谢后果，特别有必要在系统水平上研究脂质过程。我们推测，一般人群肝脏中各种脂质及其代谢产物的含量是受遗传因素显著控制的数量性状;这些遗传位点的发现可以更好地了解肝脏脂肪蓄积和相关疾病。为了实现这一目标，我们建议使用大量肝脏组织（n=213）进行全面的脂质组遗传作图，其中总脂肪含量是有区别的，并且之前已经收集了全基因组基因型和转录组数据。我们将：1）在213个肝脏中的每一个中分析>400种不同的脂质; 2）进行全基因组关联研究以鉴定与肝脏脂质组变化相关的多态性和基因;以及3）在独立的肝脏样品组（n=70）中验证所发现的关联。我们预计，这项研究将确定关键基因，等位基因和途径赋予人类肝脏中不平衡脂质积累的易感性，从而为NAFLD和相关疾病的早期诊断和干预提供潜在的标志物和靶点。 公共卫生相关性：这项研究将发现负责人类肝脏中脂肪和脂肪组分积累的基因和DNA变体，这是非酒精性脂肪肝病和许多其他代谢疾病的标志，例如肥胖和糖尿病。这项研究将为更好地了解这些疾病的发展提供重要信息。该研究还将潜在地确定可用于开发更好治疗的分子靶点。

DESCRIPTION (provided by applicant): The ultimate goal of this study is to identify genetic factors controlling the accumulation of various lipids in human liver, using a system approach with integrated genomic and lipidomic (i.e. lipids family) data. Hepatic fat accumulation is a hallmark of nonalcoholic fatty liver disease (NAFLD) and various metabolic complications. Its mechanism, especially the genetic basis underlying the fat accumulation, is incompletely elucidated. This is largely attributed to insufficient understanding of the complexity of lipid metabolism and homeostasis. Since a wide range of lipids are involved in fat accumulation and the associated metabolic consequences, it is particularly necessary to investigate the lipid process at the system level. We hypothesize that the contents of various lipids and their metabolites in the livers of the general population are quantitative traits significantly controlled by genetic factors; and the discovery of these genetic loci could provide better insight on the hepatic fat accumulation and associated diseases. To accomplish this, we propose to perform a comprehensive genetic mapping for lipidome using a large collection of liver tissues (n=213) in which the total fat content is differentiated, and for which genome-wide genotypic and transcriptomic data have been previously collected. We will: 1) profile >400 different lipids in each of the 213 livers; 2) perform genome-wide association study to identified polymorphisms and genes associated with variations in hepatic lipidome; and 3) validate the discovered associations in an independent liver sample set (n=70). We anticipate that this study will identify critical genes, alleles and pathways conferring susceptibility to imbalanced lipid accumulation in human liver, and will thus provide potential markers and targets for early diagnosis and intervention of NAFLD and related diseases. PUBLIC HEALTH RELEVANCE: This study will discover genes and DNA variants responsible for the accumulation of fat and fat fractions in human liver, a hallmark of nonalcoholic fatty liver disease and many other metabolic diseases, e.g. obesity and diabetes. This study will produce important information for attaining a better understanding of the development of these diseases. The study will also potentially identify molecular targets that could be used to develop better treatment.